[Therapy of ventricular tachyarrhythmia with disopyramid phosphate].
A controlled multicenter study has been carried out in 46 patients with ventricular tachyarrhythmias to define the antiarrhythmic effect of disopyramide phosphate. Monitoring of cardiac rhythm was performed during the whole study period by ambulatory Holter recording. The daily dose of disopyramide was 600 mg. It was found that disopyramide caused a reduction  of at least 80% in the number of premature ventricular beats in 72% of the patients. Episodes of ventricular tachycardia were effectively suppressed in 65% of the patients. In 24 patients there was a reduction in the severity of the observed ventricular arrhythmias of at least one class in the classification of Lown. Analysis of the results showed a relationship between the antiarrhythmic effect and group mean plasma concentration of disopyramide.
D000328:Adult; D004206:Disopyramide / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000627:therapeutic use*; D013610:Tachycardia / Q000188:drug therapy*
D011725:Pyridines; D004206:Disopyramide
Therapie ventrikulärer Tachyarrhythmien mit Disopyramid-Phosphat.